Drug Trial Radar · NCT03630952
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
Last checked: Nov 20, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,157
Actual
Start
Dec 21, 2018
Primary completion
Sep 10, 2020
Study completion May 19, 2021
Sponsor
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
0.5 mg Conbercept Intravitreal InjectionBiological
Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
1.0 mg Conbercept Intravitreal InjectionBiological
Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
2.0 mg Aflibercept Intravitreal InjectionBiological
Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eyeTime frame: Baseline to Week 36
Locations
154 sites in 12 countries. Site status is shown where the registry gives one.
Kanghong Investigative Site
Phoenix, Arizona
Kanghong Investigative Site
Phoenix, Arizona
Kanghong Investigative Site
Springdale, Arkansas
Kanghong Investigative Site
Arcadia, California
Kanghong Investigative Site
Arcadia, California
Kanghong Investigative Site
Bakersfield, California
Kanghong Investigative Site
Encino, California
Kanghong Investigative Site
Glendale, California
Kanghong Investigative Site
Glendora, California
Kanghong Investigative Site
Huntington Beach, California
Kanghong Investigative Site
Pasadena, California
Kanghong Investigative Site
Poway, California
Kanghong Investigative Site
Redlands, California
Kanghong Investigative Site
Redlands, California
Kanghong Investigative Site
Riverside, California
Kanghong Investigative Site
San Francisco, California
Kanghong Investigative Site
Santa Barbara, California
Kanghong Investigative Site
Colorado Springs, Colorado
Kanghong Investigative Site
Waterford, Connecticut
Kanghong Investigative Site
Boynton Beach, Florida
Kanghong Investigative Site
Bradenton, Florida
Kanghong Investigative Site
Miami, Florida
Kanghong Investigative Site
Miami, Florida
Kanghong Investigative Site
Stuart, Florida
Kanghong Investigative Site
Winter Haven, Florida
Kanghong Investigative Site
Atlanta, Georgia
Kanghong Investigative Site
Augusta, Georgia
Kanghong Investigative Site
Marietta, Georgia
Kanghong Investigative Site
Elmhurst, Illinois
Kanghong Investigative Site
Indianapolis, Indiana
Kanghong Investigative Site
New Albany, Indiana
Kanghong Investigative Site
Leawood, Kansas
Kanghong Investigative Site
Springfield, Massachusetts
Kanghong Investigative Site
Grand Rapids, Michigan
Kanghong Investigative Site
Traverse City, Michigan
Kanghong Investigative Site
St Louis, Missouri
Kanghong Investigative Site
Reno, Nevada
Kanghong Investigative Site
Northfield, New Jersey
Kanghong Investigative Site
Teaneck, New Jersey
Kanghong Investigative Site
Albuquerque, New Mexico
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.